Skip to main content
SpringerLink
Log in

AML in Older Adults

  • Chapter
Acute Myelogenous Leukemia

Part of the book series: Contemporary Hematology ((CH))

  • 1179 Accesses

Abstract

Older adults with acute myeloid leukemia (AML) present a complex array of therapeutic dilemmas. As a result of host factors making chemotherapy less well tolerated, and disease factors making response to antineoplastic strategies less likely, difficult decisions abound. Therapeutic options, including aggressive chemotherapy, supportive care, or less intense therapy (e.g., clinical trials), have vastly different implications. The choice among these requires prolonged discussions with the patient and family members. Because of the poor results obtained in this age group, there is a need for the development of novel targeted, less toxic, and more effective therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bennett J, Catovsky D, Daniel M, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British cooperative group. Ann Int Med 1985;103:620.

    CAS  PubMed  Google Scholar 

  2. Fenaux P, Chomienne C, Degos L. Acute promyelocytic leukemia: biology and treatment. Semin Oncol 1997; 24:92–102.

    CAS  PubMed  Google Scholar 

  3. Tallman MS, Nabhan C, Feusner JH, et al. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002;99:759–767.

    Article  CAS  PubMed  Google Scholar 

  4. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292–2302.

    Article  CAS  PubMed  Google Scholar 

  5. Estey E, Thall P, Beran M, et al. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 1997;90:2969–2977.

    CAS  PubMed  Google Scholar 

  6. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312–1320.

    Article  CAS  PubMed  Google Scholar 

  7. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 1998;92:2322–2333.

    CAS  PubMed  Google Scholar 

  8. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325–4336.

    Article  CAS  PubMed  Google Scholar 

  9. Kottaridis PD, Gale RE, Linch DC. Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia. Leuk Lymphoma 2003;44:905–913.

    Article  CAS  PubMed  Google Scholar 

  10. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997;89:3323–3329.

    CAS  PubMed  Google Scholar 

  11. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896–903.

    Article  CAS  PubMed  Google Scholar 

  12. Beghe C, Balducci L. Biological basis of cancer in the older person. Cancer Treat Res 2005;124:189–221.

    Article  PubMed  Google Scholar 

  13. Wiernik PH, Banks PL, Case DC, Jr., et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992;79: 313–319.

    CAS  PubMed  Google Scholar 

  14. Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 2002;100:3869–3876.

    Article  CAS  PubMed  Google Scholar 

  15. Rowe J, Neuberg D, Friedenberg W, et al. A Phase III study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479–485.

    Article  CAS  PubMed  Google Scholar 

  16. Bishop JF, Matthews JP, Young GA, et al. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Leuk Lymphoma 1998;28:315–327.

    CAS  PubMed  Google Scholar 

  17. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996;88:2841–2851.

    CAS  PubMed  Google Scholar 

  18. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council’s 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 1997;89:2311–2318.

    CAS  PubMed  Google Scholar 

  19. Ossenkoppele GJ, Graveland WJ, Sonneveld P, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood 2004;103:2908–2913.

    Article  CAS  PubMed  Google Scholar 

  20. Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002;100:1224–1232.

    CAS  PubMed  Google Scholar 

  21. Stone R, Berg D, George S, et al. Post-remission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 2001;98:548–553.

    Article  CAS  PubMed  Google Scholar 

  22. Bloomfield C. Postremission therapy in acute myeloid leukemia. J Clin Oncol 1985;3:1570–1572.

    CAS  PubMed  Google Scholar 

  23. Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy—the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998;16:872–881.

    CAS  PubMed  Google Scholar 

  24. Jurcic J. Treating Acute Promyelocytic Leukemia in the Older Patient. The Am J Oncol Rev 2005;4: 344–349.

    Google Scholar 

  25. Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-transretinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004;103:1237–1243.

    Article  CAS  PubMed  Google Scholar 

  26. Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999;94:3015–3021.

    CAS  PubMed  Google Scholar 

  27. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999;94:1192–1200.

    CAS  PubMed  Google Scholar 

  28. Gorin NC. Autologous stem cell transplantation in acute myelocytic leukemia. Blood 1998;92:1073–1090.

    CAS  PubMed  Google Scholar 

  29. Yeager AM, Kaizer H, Santos GW, et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 1986;315:141–147.

    Article  CAS  PubMed  Google Scholar 

  30. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390–3400.

    Article  CAS  PubMed  Google Scholar 

  31. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005;105:1810–1814.

    Article  CAS  PubMed  Google Scholar 

  32. Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989;7:1268–1274.

    CAS  PubMed  Google Scholar 

  33. Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990;8:272–279.

    CAS  PubMed  Google Scholar 

  34. Sekeres MA, Stone RM, Zahrieh D, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2004;18:809–816.

    Article  CAS  PubMed  Google Scholar 

  35. Vallenga E, Ostapovicz D, O’Rourke B, et al. Effects of recombinant K-3, GM-CSF on proliferation of leukemic clonogenic eeks in short term and long term cultures. Leukemia 1987;1:584–589.

    Google Scholar 

  36. Schiffer CA. Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 1996;88:3675–3685.

    CAS  PubMed  Google Scholar 

  37. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocytemacrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457–462.

    CAS  PubMed  Google Scholar 

  38. Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colonystimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med 1995;332:1678–1683.

    Article  CAS  PubMed  Google Scholar 

  39. Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997;90:4710–4718.

    CAS  PubMed  Google Scholar 

  40. Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995;85:2643–2653.

    CAS  PubMed  Google Scholar 

  41. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354–3360.

    CAS  PubMed  Google Scholar 

  42. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852–3860.

    CAS  PubMed  Google Scholar 

  43. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341–1348.

    Article  CAS  PubMed  Google Scholar 

  44. Sievers EL. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid laukaemia in first relapse. Expert Opin Biol Ther 2001;1:893–901.

    Article  CAS  PubMed  Google Scholar 

  45. Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003;102:1578–1582.

    Article  CAS  PubMed  Google Scholar 

  46. Giles F, Estey E, O’Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 2003;98:2095–2104.

    Article  CAS  PubMed  Google Scholar 

  47. Amadori S, Suciu S, Stasi R, et al. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organization for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell’ Adulto Leukemia Groups. Leukemia 2005;19:1768–1773.

    Article  CAS  PubMed  Google Scholar 

  48. Estey EH, Thall PF, Giles FJ, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002;99:4343–4349.

    Article  CAS  PubMed  Google Scholar 

  49. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102:2379–2386.

    Article  CAS  PubMed  Google Scholar 

  50. Giles FJ, Feldman EJ, Roboz GJ, et al. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leukemia Res 2003;27:1091–1096.

    Article  CAS  Google Scholar 

  51. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532–1542.

    Article  CAS  PubMed  Google Scholar 

  52. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004;103:3669–3676.

    Article  CAS  PubMed  Google Scholar 

  53. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005;105:54–60.

    Article  CAS  PubMed  Google Scholar 

  54. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001;97:3361–3369.

    Article  CAS  PubMed  Google Scholar 

  55. Harousseau JL, Reiffers J, Lowenberg J, et al. Zarnestra (R115777) in patients with relapsed and refractory acute myelogenous leukemia (AML): results of a multicenter Phase II study. Blood 2003;102:176a[614].

    Google Scholar 

  56. Lancet JE, Karp JE. Farnesyl transferase inhibitors in myeloid malignancies. Blood 2003;17:123–129.

    Article  Google Scholar 

  57. Greenberg PL, Lee SJ, Advani R, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 2004;22:1078–1086.

    Article  CAS  PubMed  Google Scholar 

  58. List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001;98:3212–3220.

    Article  CAS  PubMed  Google Scholar 

  59. Marcucci G, Byrd JC, Dai G, et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 2003; 101:425–432.

    Article  CAS  PubMed  Google Scholar 

  60. Attar EC, De Angelo DJ, Ballen KK, et al. Phase I Dose Escalating Trial of Bortezomid (Velcade) in Combination with Idarubicin and Cytarabine in Patients with Acute Myeloid Leukemia. Blood 2004;104: 498 a[1799].

    Google Scholar 

  61. Omura GA, Vogler WR, Lefante J, et al. Treatment of acute myelogenous leukemia: influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy. Cancer 1982;49:1530–1536.

    Article  CAS  PubMed  Google Scholar 

  62. Dunussi-Joannopoulos K, Runyon K, Erickson J, et al. Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity. Blood 1999;94: 4263–4273.

    CAS  PubMed  Google Scholar 

  63. DeAngelo DJ. A Phase I study of vaccination with lethally irradiated, autologous myeloblasts engineered by adenoviral mediated gene transfer to secrete human granulocyte-macrophase colony stimulating factor. Blood 2001;98:463a.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adult Leukemia Program, Dana Farber Cancer Institute, Boston, Massachusetts

    Richard M. Stone (Clinical Director, Associate Professor of Medicine)

  2. Harvard Medical School, Boston, Massachusetts

    Richard M. Stone (Clinical Director, Associate Professor of Medicine)

Authors
  1. Richard M. Stone
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

    Judith E. Karp MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Stone, R.M. (2007). AML in Older Adults. In: Karp, J.E. (eds) Acute Myelogenous Leukemia. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-322-6_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-322-6_18

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-621-4

  • Online ISBN: 978-1-59745-322-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation